Literature DB >> 30535888

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

S Sebastian1,2, S Myers3, S Nadir3, S Subramanian4.   

Abstract

BACKGROUND: Pharmacokinetic data suggest that standard induction dosing schedules may not be sufficient in patients with acute severe colitis (ASUC). Hence, intensified induction regimes are increasingly used in the rescue treatment of hospitalized patients with ASUC to avoid the need for colectomy although the evidence for this is uncertain. AIM: To conduct a systematic review of short- and long-term efficacy outcomes from accelerated infliximab induction studies.
METHODS: Systematic search of relevant databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews) and relevant conference proceedings (Digestive Diseases Week, European Colitis and Crohn's Organisation Congress, United European Gastroenterology Week) was done.
RESULTS: We identified ten relevant studies with a total of 705 patients, of whom 308 received an intensified infliximab regime. Pooled analysis showed no difference in short-term or long-term colectomy rates in those receiving accelerated induction regimes when compared to standard induction. No significant differences in complication rates were identified.
CONCLUSIONS: The available uncontrolled studies so far do not suggest short-term or long-term benefit in using accelerated induction in hospitalized ASUC. The overall poor quality of available studies with confounding variables indicates the need for a randomized controlled trial with personalized risk stratification.

Entities:  

Keywords:  Accelerated induction; Acute severe UC; Infliximab; Rescue therapy

Mesh:

Substances:

Year:  2018        PMID: 30535888     DOI: 10.1007/s10620-018-5407-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.

Authors:  M Chaparro; P Burgueño; E Iglesias; J Panés; F Muñoz; G Bastida; L Castro; C Jiménez; J L Mendoza; M Barreiro-de Acosta; S Gómez Senent; F Gomollón; X Calvet; E García-Planella; M Gómez; V Hernández; J Hinojosa; M Mañosa; O Pérez Nyssen; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2011-12-05       Impact factor: 8.171

2.  A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.

Authors:  C W Lees; D Heys; G T Ho; C L Noble; A G Shand; C Mowat; R Boulton-Jones; A Williams; N Church; J Satsangi; I D R Arnott
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

3.  A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule.

Authors:  Rymon Rofaiel; Sonny Kohli; Marco Mura; Seyed M Hosseini-Moghaddam
Journal:  BMJ Case Rep       Date:  2017-05-12

Review 4.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

5.  Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

Authors:  Shailja C Shah; Steven Naymagon; Hinaben J Panchal; Bruce E Sands; Benjamin L Cohen; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2018-02-15       Impact factor: 5.325

6.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

7.  Predicting response after infliximab salvage in acute severe ulcerative colitis.

Authors:  Matthew C Choy; Dean Seah; Alexandra Gorelik; Yoon-Kyo An; Cheng-Yu Chen; Finlay A Macrae; Miles P Sparrow; William R Connell; Gregory T Moore; Graham Radford-Smith; Daniel R Van Langenberg; Peter De Cruz
Journal:  J Gastroenterol Hepatol       Date:  2018-02-27       Impact factor: 4.029

8.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

9.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

10.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

View more
  7 in total

1.  Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis.

Authors:  Pauline Rivière; David Laharie; Philippe Marteau
Journal:  Dig Dis Sci       Date:  2020-02       Impact factor: 3.199

2.  How to manage: acute severe colitis.

Authors:  Thomas Edward Conley; Joseph Fiske; Sreedhar Subramanian
Journal:  Frontline Gastroenterol       Date:  2021-02-17

3.  Infliximab in acute severe colitis: getting the right dose.

Authors:  Joseph Fiske; Thomas Conley; Shaji Sebastian; Sreedhar Subramanian
Journal:  Frontline Gastroenterol       Date:  2020-04-03

4.  Practice pattern variability in the management of acute severe colitis: a UK provider survey.

Authors:  Shaji Sebastian; Jessica Lisle; Sreedhar Subramanian; Anjan Dhar; Achut Shenoy; Jimmy Limdi; Jeffrey Butterworth; Patrick B Allen; Sunil Samuel; Gordon Moran; Richard Shenderey; Gareth Parkes; Tim Raine; Alan J Lobo; Nicholas A Kennedy
Journal:  Frontline Gastroenterol       Date:  2019-08-17

5.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

6.  Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.

Authors:  Shaji Sebastian; Gareth J Walker; Nicholas A Kennedy; Thomas E Conley; Kamal V Patel; Sreedhar Subramanian; Alexandra J Kent; Jonathan P Segal; Matthew J Brookes; Neeraj Bhala; Haidee A Gonzalez; Lucy C Hicks; Shameer J Mehta; Christopher A Lamb
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-02-02

7.  Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report.

Authors:  Ana Lorena Sousa de Vasconcelos Garate; Thiara Barcelos Rocha; Luciana Rocha Almeida; Rodrigo Quera; Jaqueline Ribeiro Barros; Julio Pinheiro Baima; Rogerio Saad-Hossne; Ligia Yukie Sassaki
Journal:  World J Clin Cases       Date:  2021-05-06       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.